Stocks Industrials TXG
NASDAQ · Industrials10x Genomics, Inc. (TXG)
10x Genomics, Inc. brought in $616.9M of revenue over the twelve months to June 30, 2026, down 4.3% from a year earlier. It posted a net loss of $75.1M. Operating cash flow minus capital spending left $130.1M of free cash flow in fiscal 2025. At June 30, 2026 it held $502.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
What 10x Genomics, Inc. does
10x Genomics, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker TXG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $642.8M | -$43.5M | -$0.35 | $130.1M |
| 2024 | $610.8M | -$182.6M | -$1.52 | -$5.7M |
| 2023 | $618.7M | -$255.1M | -$2.18 | -$63.8M |
| 2022 | $516.4M | -$166M | -$1.46 | -$165.3M |
| 2021 | $490.5M | -$58.2M | -$0.53 | -$122.7M |
| 2020 | $298.8M | -$542.7M | -$5.37 | -$254.6M |
Latest SEC filings
What 10x Genomics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 8, 2026
- May 8, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
- April 28, 2026Passive stake (5% or more) SCHEDULE 13G
- April 24, 2026Additional proxy material DEFA14A
Questions about TXG
What does 10x Genomics, Inc. do?
10x Genomics, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker TXG.
Is 10x Genomics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $75.1M on revenue of $616.9M.
How much revenue does 10x Genomics, Inc. make?
Over the twelve months to June 30, 2026 10x Genomics, Inc. reported revenue of $616.9M. That is 4.3% less than a year earlier.
When did 10x Genomics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Follow TXG
Get an email when 10x Genomics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TXG: get an email when it filesWhere the numbers come from
Financial figures are the values 10x Genomics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.